SQUIRE_2B | R Documentation |
Kaplan-Meier digitized data from SQUIRE, figure 2B (PMID 26045340). A reported sample size of 1,093 for a primary endpoint of OS in lung cancer.
SQUIRE_2B
A data frame of 1,093 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (gem_cis, necitumumab_gem_cis) | |
Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16: 763–74.
summary(SQUIRE_2B)
kmplot(SQUIRE_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.